[Current diagnostics and therapy in chronic rhinosinusitis].

Area of Science:

• Otolaryngology
• Immunology
• Pharmacology

Background:

• Chronic rhinosinusitis (CRS) is a widespread condition with substantial patient and societal impact.
• Current diagnostic and treatment strategies, guided by EPOS2020 guidelines, increasingly focus on molecular mechanisms and phenotypes.
• Biologics represent a novel therapeutic avenue for refractory CRS cases.

Purpose of the Study:

• To review the evolving landscape of chronic rhinosinusitis management.
• To highlight the role and considerations for biologic therapies in CRS.
• To emphasize the need for personalized treatment and multidisciplinary collaboration.

Main Methods:

• Literature review of current guidelines and emerging therapies for CRS.
• Analysis of the role of biologics in managing complex CRS phenotypes.
• Discussion of comorbidity management and cost-effectiveness of advanced treatments.

Main Results:

• Biologics show promise for severe and refractory chronic rhinosinusitis.
• Effective management requires addressing comorbidities alongside CRS.
• Personalized patient assessment is essential due to high biologic therapy costs.

Conclusions:

• The advent of biologics necessitates a more personalized and integrated approach to CRS management.
• Multidisciplinary expert boards are crucial for optimizing treatment recommendations.
• Future strategies must balance therapeutic innovation with economic considerations and individual patient needs.